AKT1 and COVID-19: The XBJ injection may inhibit the lipopolysaccharide-mediated inflammatory response, modulate NOS activity, and regulate the TNF signaling pathway by affecting the function of the AKT1, thereby ultimately suppressing the excessive inflammatory response associated with COVID-19.